# BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas

> **NCT03749187** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **University of California, San Francisco** · enrollment: 78 (estimated)

## Conditions studied

- Glioblastoma
- IDH1 Gene Mutation
- IDH2 Gene Mutation
- Low Grade Glioma
- Malignant Glioma
- Recurrent Glioblastoma
- Recurrent WHO Grade II Glioma
- Recurrent WHO Grade III Glioma
- WHO Grade II Glioma
- WHO Grade III Glioma

## Interventions

- **DRUG:** PARP Inhibitor BGB-290
- **DRUG:** Temozolomide (TMZ)

## Key facts

- **NCT ID:** NCT03749187
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-03
- **Primary completion:** 2026-06-30
- **Final completion:** 2029-07-30
- **Target enrollment:** 78 (ESTIMATED)
- **Last updated:** 2026-03-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03749187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03749187, "BGB-290 and Temozolomide in Treating Isocitrate Dehydrogenase (IDH)1/2-Mutant Grade I-IV Gliomas". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03749187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*